Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS).  Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications, and sometimes death.

Biotechnology

Inhalon

John Whelan

Bill Picht

Brian Farrer

Jeff Hutchins

Thomas Moench

Sam Lai

The founding team at Inhalon has a long history of experience in the field of pharmacy and engineering. The team includes a professor from UNC, the founder and CEO of Mucommune, and an associate professor from the University of North Carolina. All three members of the team have degrees in chemical and biomolecular engineering from Cornell University and The Johns Hopkins University.

Founding Team

Leadership Team

CEO and Executive Team

Board of Directors

Founding Team

About

Team members

Other teams at Inhalon

Leadership Team

CEO and Executive Team

Board of Directors